Los Angeles Capital Management’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $36.2K | Hold |
210
| – | – | ﹤0.01% | 1565 |
|
|
2025
Q4 | $37.6K | Buy |
+210
| New | +$38.1K | ﹤0.01% | 1685 |
|
|
2025
Q3 | – | Sell |
-5,265
| Closed | -$799K | – | 1392 |
|
|
2025
Q2 | $799K | Sell |
5,265
-3,530
| -40% | -$471K | ﹤0.01% | 712 |
|
|
2025
Q1 | $1.32M | Buy |
+8,795
| New | +$1.47M | 0.01% | 489 |
|
|
2021
Q4 | – | Sell |
-5,209
| Closed | -$2.15M | – | 1410 |
|
|
2021
Q3 | $2.15M | Sell |
5,209
-1,455
| -22% | -$604K | 0.01% | 516 |
|
|
2021
Q2 | $2.46M | Sell |
6,664
-2,543
| -28% | -$849K | 0.01% | 543 |
|
|
2021
Q1 | $2.67M | Sell |
9,207
-3,420
| -27% | -$951K | 0.01% | 545 |
|
|
2020
Q4 | $3.15M | Sell |
12,627
-43
| -0.3% | -$10.2K | 0.01% | 513 |
|
|
2020
Q3 | $2.87M | Sell |
12,670
-64
| -0.5% | -$13.3K | 0.01% | 479 |
|
|
2020
Q2 | $2.22M | Buy |
12,734
+456
| +4% | +$72.8K | 0.01% | 585 |
|
|
2020
Q1 | $1.55M | Sell |
12,278
-5,950
| -33% | -$892K | 0.01% | 604 |
|
|
2019
Q4 | $2.79M | Sell |
18,228
-108,274
| -86% | -$15M | 0.01% | 551 |
|
|
2019
Q3 | $16.7M | Buy |
126,502
+57,561
| +83% | +$7.72M | 0.09% | 207 |
|
|
2019
Q2 | $9.78M | Buy |
68,941
+9,099
| +15% | +$1.23M | 0.05% | 308 |
|
|
2019
Q1 | $8.69M | Buy |
59,842
+45,390
| +314% | +$5.96M | 0.05% | 333 |
|
|
2018
Q4 | $1.64M | Sell |
14,452
-2,250
| -13% | -$282K | 0.01% | 608 |
|
|
2018
Q3 | $2.25M | Buy |
16,702
+260
| +2% | +$32.1K | 0.01% | 640 |
|
|
2018
Q2 | $1.85M | Buy |
16,442
+100
| +0.6% | +$10.8K | 0.01% | 714 |
|
|
2018
Q1 | $1.74M | Buy |
16,342
+3,000
| +22% | +$323K | 0.01% | 674 |
|
|
2017
Q4 | $1.46M | Hold |
13,342
| – | – | 0.01% | 757 |
|
|
2017
Q3 | $1.44M | Buy |
13,342
+171
| +1% | +$17.6K | 0.01% | 706 |
|
|
2017
Q2 | $1.33M | Buy |
13,171
+200
| +2% | +$18.4K | 0.01% | 695 |
|
|
2017
Q1 | $1.17M | Sell |
12,971
-2,350
| -15% | -$200K | 0.01% | 679 |
|
|
2016
Q4 | $1.17M | Hold |
15,321
| – | – | 0.01% | 663 |
|
|
2016
Q3 | $1.28M | Sell |
15,321
-154
| -1% | -$12.9K | 0.01% | 671 |
|
|
2016
Q2 | $1.28M | Sell |
15,475
-4,156
| -21% | -$342K | 0.01% | 648 |
|
|
2016
Q1 | $1.49M | Sell |
19,631
-12,900
| -40% | -$955K | 0.01% | 532 |
|
|
2015
Q4 | $2.62M | Sell |
32,531
-4,630
| -12% | -$334K | 0.02% | 447 |
|
|
2015
Q3 | $2.36M | Sell |
37,161
-1,970
| -5% | -$141K | 0.02% | 506 |
|
|
2015
Q2 | $2.75M | Hold |
39,131
| – | – | 0.03% | 496 |
|
|
2015
Q1 | $3.1M | Sell |
39,131
-4,319
| -10% | -$319K | 0.03% | 452 |
|
|
2014
Q4 | $2.77M | Sell |
43,450
-555
| -1% | -$34.8K | 0.03% | 422 |
|
|
2014
Q3 | $2.63M | Buy |
44,005
+28,320
| +181% | +$1.62M | 0.03% | 395 |
|
|
2014
Q2 | $839K | Buy |
15,685
+5,785
| +58% | +$317K | 0.01% | 728 |
|
|
2014
Q1 | $597K | Hold |
9,900
| – | – | 0.01% | 817 |
|
|
2013
Q4 | $525K | Buy |
+9,900
| New | +$497K | 0.01% | 883 |
|
Other funds holding CRL
VCM
VPM
Los Angeles Capital Management's CRL Position: Q1 2026 in Review
Los Angeles Capital Management held its Charles River Laboratories (CRL) position steady in Q1 2026 at 210 shares worth $36.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1565.
Los Angeles Capital Management first reported a position in CRL in Q4 2013 and has held it in 36 quarters since. The position peaked at $16.7M in Q3 2019. 558 funds tracked by Wall St. Rank hold CRL as of Q1 2026.
- Los Angeles Capital Management held 210 shares of Charles River Laboratories worth $36.2K as of Q1 2026.
- Los Angeles Capital Management left its Charles River Laboratories share count unchanged in Q1 2026.
- Charles River Laboratories made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #1565 holding.
- Los Angeles Capital Management first reported a position in Charles River Laboratories in Q4 2013 and has held it in 36 quarters since.
- Los Angeles Capital Management's Charles River Laboratories position peaked at $16.7M in Q3 2019.
- 558 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.
Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.